On November 5, 2026 ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, reported two publications providing new nonclinical evidence and scientific insights into the ability of its novel stimulator of interferon genes (STING) agonist, IMGS-203, to remodel the tumor microenvironment and enhance antitumor activity in combination with the Company’s novel cytotoxic dual-specific PD-L1/PD-L2 antibody.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IMGS-203 is a novel STING agonist being developed by ImmunoGenesis as a cancer immunotherapy designed to stimulate antitumor immune responses. The Company plans to advance IMGS-203 into clinical development initially for recurrent glioblastoma (GBM), an aggressive brain cancer with limited therapeutic options and significant unmet medical need.
Dr. Federica Pericle, Chief Scientific Officer, ImmunoGenesis, commented: "These findings reinforce the scientific rationale for developing IMGS-203 in GBM, where local STING activation has the potential to overcome the immunosuppressive tumor microenvironment. We are completing IND-enabling studies to advance IMGS-203 into clinical development while exploring its potential in combination with our cytotoxic dual-specific PD-L1/PD-L2 antibody."
The data from these publications are directly relevant to GBM, a highly immunosuppressive, myeloid-rich tumor in which monotherapy with conventional immune checkpoint inhibitors have shown limited efficacy. Nonclinical studies demonstrate that local administration of IMGS-203 remodels the tumor microenvironment (TME), reduces immunosuppressive myeloid cell populations, enhances T-cell activation, and improves survival in tumor models. STING activation also induces PD-L1 and PD-L2 expression, creating an opportunity to enhance antitumor activity through combination with ImmunoGenesis’ cytotoxic dual-specific PD-L1/PD-L2 antibody.
"Together, these publications reinforce our commitment to translating STING biology into innovative cancer therapies," said James Barlow, President and Chief Executive Officer, ImmunoGenesis. "We are focused on advancing IMGS-203 into clinical development for patients with GBM, a devastating disease with limited treatment options and significant unmet clinical need."
Publication Details:
Salameh, et al., (2026), Tumor Microenvironment Remodeling by STING Agonism Sensitizes Endothelial Cells to Cytotoxic anti-PD-L1/L2 Antibody in Journal of Experimental and Clinical Cancer Research highlights promising results showing activation of the STING pathway can overcome immune exclusion by promoting Tumor Microenvironment (TME) remodeling and immune cell recruitment.
Boda et al., (2026) "STING-Mediated Tumor Microenvironment Remodeling: Turning Adaptive Resistance into Therapeutic Vulnerability." Frontiers in Immunology reviews data showing how STING activation can reconfigure the TME to yield potent anti-tumor effects.
(Press release, ImmunoGenesis, NOV 5, 2026, View Source [SID1234674352])